胰升糖素样肽1：非酒精性脂肪性肝病治疗的新靶点？  

Glucagon-like peptide-1 ： New target for treating non-alcoholic fatty liver disease？

作　　者：刘烨[1] 洪天配[1] 魏蕊[1] 杨进[1] 

机构地区：[1]北京大学第三医院内分泌科,100191

出　　处：《中华内分泌代谢杂志》2015年第5期386-389,共4页Chinese Journal of Endocrinology and Metabolism

基　　金：国家973计划资助项目（2012CB517502）;国家自然科学基金资助项目（81270858、81401142、81400767、81400798）;高等教育博士学科点新教师基金资助项目（20120001120069）

摘　　要：非酒精性脂肪性肝病（NAFLD）患者存在胰升糖素样肽1（GLP-1）信号受损。天然GLP-1或GLP-1类药物可通过GLP-1受体对肝细胞发挥直接作用，包括改善胰岛素抵抗、抑制氧化应激、调控脂代谢相关基因表达等。临床研究显示GLP-1类药物能够改善NAFLD患者的代谢指标和肝脏病变。Recent studies have demonstrated an association of glucagon-like peptide-1 （ GLP-1 ） signaling defect with non-alcoholic fatty liver disease （NAFLD）. Native GLP-1 and GLP-l-based agents may directly act on hepatocytes through activation of GLP-1 receptors in hepatocytes, resulting in the regulation of gene expression associated with insulin resistance and lipid metabolism, and the suppression of oxidative stress in liver cells. Moreover, GLP-1-based agents have been reported to be effective in improving hepatic endpoints in patients with NAFLD.

关 键 词：非酒精性脂肪性肝病 胰升糖素样肽1 二肽基肽酶4 

分 类 号：R575.5[医药卫生—消化系统]